Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 677-683

  Morgan, Todd M ^a,c   Lange, Paul H ^a   Porter, Michael P ^a,b   Lin, Daniel W ^a,b   Ellis, William J ^a   Gallaher, Ian S ^a   Vessella, Robert L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Puget Sound VA Health Care System   (United States)

^c Box 356510 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD61 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISSEMINATED CANCER; EPITHELIOID CELL; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; BONE MARROW CELLS; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 59449087476     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1754     Document Type: Article

References (36)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
2. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-5.
3. Meng SD, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
4. Schmidt-Kittler 0, Ragg T, Daskalis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003;100:7737-42.
5. Klein CA, Blankenstein JF, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
6. Klein C, Holzel D. Systemic cancer progression and tumor dormancy. Cell Cycle 2006;5:1788-98.
7. Bianco FJ, Wood DP, Gomes de Oliveira J, Nemeth JA, Beamann AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 2001;49:235-42.
8. Pfitzenmaier J, Ellis WJ, Hawley S, et al. The detection and isolation of prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007;25:214-20.
9. Brandt B, Junker R, Griwatz C, et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 1996;56:4556-61.
10. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003;61:277-81.
11. Gao CL, Rawal SK, Sun L, et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res 2003;9:2545-50.
12. Morgan T, Lange P, Vessella R. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007;12:3000-9.
13. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
14. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
15. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62.
16. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG; Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005;65:713-8.
17. Weckermann D, Wawroschek F, Krawckak G, Haude KH, Harzmann R. Does the immunocyto-chemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy? Urol Res 1999;27:285-90.
18. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146-51.
19. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Urol 2006;24:3973-8.
20. Berg A, Berner A, Lilleby W, Fossa S, Nesland J, Kvalheim G. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmeta-static prostate cancer treated by definitive radiotherapy. Int J Cancer 2007;120:1603-9.
21. Thomas J, Gupta M, Grasso Y, et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 2002;20:3213-8.
22. Weckermann D, Muller P, Wawroschek F, Krawczak G, Reithmuller G, Schlimok G. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol 1999;17:3438-43.
23. Wood DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997;15:3451-7.
24. Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 2006;66:8959-65.
25. Holcomb IN, Grove Dl, Kinnunen M, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008;68:1-10.
26. Millon R, Jacqmin D, Muller D, Guillot J, Eber M, Abecassis J. Detection of prostate-specific antigen or prostate-specific antigen-positive circulating cells in prostatic cancer patients: clinical implications. Eur Urol 1999;36:278-85.
27. Tombal B, Van Cangh P, Loric S, Gala J. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 2003;56:163-70.
28. Lilleby W, Nesland J, Fossa S.Torlakovic G. Waehre H, Kvalheim G. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer. Int J Cancer 2003;103:91-6.
29. Braun S, Schlimok G, Heumos I, et al. erbB2 over-expression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage l-lll breast cancer patients. Cancer Res 2001;61:1890-5.
30. Janni W, Hepp F, Rjosk D, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001;92:46-53.
31. Dyke R, McBride H, George A, Hamblin T, Stevenson F. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell Immunol 1991;132:70-83.
32. Holmgren L, O'Reilly M, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
33. Wikman H, Vessella RL, Pantel K. Cancer micro-metastasis and tumor dormancy. APMIS 2008;116:754-70.
34. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
35. Lammers R, Giesert C, Grunebach F, Marxer A, Vogel W, Buhring H. Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol 2002;30:537-45.
36. Tibbe A, Miller M, Terstappen L. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007;71:154-62.